45 mg tablet daily by mouth for six weeks

Pioglitazone

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Antigen ki-67 (Ki-67) will be assessed by immunohistochemistry.

Number of Participants With a Change in Ki-67 Due to the Effect of Pioglitazone in Tumor Tissue

Apoptotic index (A1) will be assessed by terminal deoxynucleotidyl transferase dUTP end labeling (TUNEL) and cyclin D1, p21/Waf1, PPARy, MUC1, gelsolin, proline oxidase, and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) will be assessed by immunohistochemistry.

Number of Participants With Effects of Pioglitazone on Multiple Biomarkers in Tumor

Here are the number of participants with adverse events. For details about the adverse events see the adverse event module.

Number of Participants With Adverse Events

Response will be evaluated by FDG-PET. Response is defined as a decrease of standardized uptake values (SUV) of more than one.

Number of Participants With Metabolic Activity Determined by Fludeoxyglucose Positron-emission Tomography (FDG-PET)

Premalignant tissue biomarkers ki-67, apoptotic index and peroxisome proliferator-activated receptor gamma (PPARgamma) will be assessed by immunohistochemistry.

Number of Participants With Effects of Pioglitazone on Premalignant Tissue Biomarkers

ki-67 and peroxisome proliferator-activated receptor gamma (PPARgamma) will be assessed by immunohistochemistry.

Number of Participants With Effects of Pioglitazone on Histologically Normal Tissue Biomarkers

C-reactive protein, cancer antigen 15-3 (CA 15-3), cancer antigen 125 (CA-125) and carcinoembryonic antigen (CEA) will be assessed by immunohistochemistry.

lung neoplasms/proline

Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer

Baza e të dhënave më e plotë e bimëve medicinale e mbështetur nga shkenca